Contrarius Investment Management, an investment management company, released its third-quarter investor letter for the “Contrarius Global Equity Fund”. A copy of the letter can be downloaded here. The fund’s investor class returned 30.9% in the September quarter compared to 7.3% for the benchmark MSCI World Index, including reinvested net income, and 5.5% for the Average Global Equity Fund. The fund’s investment philosophy is independent of benchmark considerations, so the portfolios typically deviate from the benchmark World Index. Additionally, please review the fund’s top five holdings to see its leading picks in 2025.
In its third-quarter 2025 investor letter, Contrarius Global Equity Fund highlighted stocks such as Intellia Therapeutics, Inc. (NASDAQ:NTLA). Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a clinical-stage gene editing company. The one-month return of Intellia Therapeutics, Inc. (NASDAQ:NTLA) was 12.84%, and its shares lost 21.61% of their value over the last 52 weeks. On December 29, 2025, Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock closed at $9.14 per share, with a market capitalization of $1.059 billion.
Contrarius Global Equity Fund stated the following regarding Intellia Therapeutics, Inc. (NASDAQ:NTLA) in its third quarter 2025 investor letter:
“Intellia Therapeutics, Inc. (NASDAQ:NTLA): Casgevy, despite being a functional cure, has some drawbacks, as one would expect from a novel technology. One drawback is the method of delivery. The treatment process involves extracting stem cells from the patient’s blood. These stem cells are then sent to a lab to be edited. Once the stem cells are ready—a month or two later—the patient undergoes a high dose of chemotherapy (called busulfan). This is done to destroy existing diseased cells, create space for modified cells, and suppress the immune system to reduce the chance of the body rejecting the edited cells. This phase is intense and has serious side effects. The patient then receives an intravenous infusion of modified cells and recovers in hospital for several weeks. The whole process is physically demanding, emotionally taxing, costly, and time consuming, taking many months from start to finish. (It’s important to point out that, in our view the upside of the treatment still materially outweighs the downside.)
For liver-related conditions, gene editing treatment regimens can be drastically superior. Scientists have figured out how to deliver the CRISPR-Cas9 directly to the relevant locations in the liver. This is known as ‘in-vivo’ editing with the treatment delivered with only one, minimally invasive intravenous infusion, and with no requirement for chemotherapy…” (Click here to read the full text)
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 31 hedge fund portfolios held Intellia Therapeutics, Inc. (NASDAQ:NTLA) at the end of the third quarter, compared to 33 in the previous quarter. Intellia Therapeutics, Inc.’s (NASDAQ:NTLA) net loss for the third quarter of 2025 was $101.3 million, down from $135.7 million for the prior year quarter. While we acknowledge the risk and potential of Intellia Therapeutics, Inc. (NASDAQ:NTLA) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Intellia Therapeutics, Inc. (NASDAQ:NTLA) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we covered Intellia Therapeutics, Inc. (NASDAQ:NTLA) and shared the list of oversold biotech stocks to invest in. In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None. This article is originally published at Insider Monkey.
